Entinostat (MS-275)

Name: Entinostat (MS-275)
Brand: Selleck Chemicals
SKU: S1053
Rating: 5 (337 reviews)

For research use only.

Catalog No.S1053 Synonyms: SNDX-275

337 publications

CAS No. 209783-80-2

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

Selleck's Entinostat (MS-275) has been cited by 337 publications

Science, 2021, 372(6537)eaba1786

PubMed: 33795428 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nat Genet, 2020, 10.1038/s41588-020-00729-3

PubMed: 33139953 ( click the link to review the publication )

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Immunol, 2014, 15(5):439-48

PubMed: 24681565 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Chem Biol, 2021, 10.1038/s41589-021-00772-z

PubMed: 33723432 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2699

PubMed: 33976188 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-20-2357

PubMed: 33994371 ( click the link to review the publication )

EMBO Rep, 2021, e52023

PubMed: 34369651 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01931-1

PubMed: 34247191 ( click the link to review the publication )

Cancer Lett, 2021, 521:268-280

PubMed: 34481935 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014

PubMed: 34482636 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13060

PubMed: 34258881 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:641987

PubMed: 34041236 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(12):16219-16228

PubMed: 34157682 ( click the link to review the publication )

Mol Neurobiol, 2021, 10.1007/s12035-021-02361-6

PubMed: 33772465 ( click the link to review the publication )
Int J Mol Sci, 2021, 22(19)10204

PubMed: 34638546 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00325-5

PubMed: 33867143 ( click the link to review the publication )

Front Oncol, 2021, 11:723966

PubMed: 34604061 ( click the link to review the publication )

J Virol, 2021, JVI0085321

PubMed: 34232065 ( click the link to review the publication )

Respir Res, 2021, 22(1):239

PubMed: 34465322 ( click the link to review the publication )

J Enzyme Inhib Med Chem, 2021, 36(1):34-47

PubMed: 33100043 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-020-1855-4

PubMed: 33420926 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2021, mcs.a006049

PubMed: 33722797 ( click the link to review the publication )

Sci Adv, 2021, 7(9)eabe3348

PubMed: 33637530 ( click the link to review the publication )

Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Protoc, 2020, 15(3):1209-1236

PubMed: 32051612 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(11):e12525

PubMed: 33026191 ( click the link to review the publication )

EMBO Rep, 2020, 4;21(3):e49254

PubMed: 32009295 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Elife, 2020, 9e59780

PubMed: 33074102 ( click the link to review the publication )

J Autoimmun, 2020, 108:102379

PubMed: 31883829 ( click the link to review the publication )

J Crohns Colitis, 2020, 14(8):1103-1118

PubMed: 32030401 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0756

PubMed: 33334730 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

J Mol Cell Cardiol, 2020, 149:73-81

PubMed: 32971072 ( click the link to review the publication )
Front Cell Dev Biol, 2020, 8:573820

PubMed: 33195208 ( click the link to review the publication )

Cell Biol Toxicol, 2020, 10.1007/s10565-020-09560-2

PubMed: 33040242 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

J Transl Med, 2020, 7;18(1):159

PubMed: 32264925 ( click the link to review the publication )

Cell Signal, 2020, 70:109573

PubMed: 32087304 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):343-356

PubMed: 31932908 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

JCI Insight, 2020, 5(4)

PubMed: 32102981 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.202048566

PubMed: 32644192 ( click the link to review the publication )

Mol Psychiatry, 2020, 10.1038/s41380-020-00958-2

PubMed: 33235333 ( click the link to review the publication )

PLoS Biol, 2020, 18(11):e3000981

PubMed: 33253182 ( click the link to review the publication )

Gastroenterology, 2019, 156(1):187-202

PubMed: 30267710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5324

PubMed: 31757943 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz1136

PubMed: 31799598 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )
J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(5):1005-1025

PubMed: 30599067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Br J Cancer, 2019, 121(12):1039-1049

PubMed: 31690832 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 10:409

PubMed: 30915074 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(7):957-972

PubMed: 31025088 ( click the link to review the publication )

J Immunol, 2019, 203(12):3199-3208

PubMed: 31732526 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31694931 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:8451282

PubMed: 30992706 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2019, 22(4):317-328

PubMed: 30668714 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Skelet Muscle, 2019, 9(1):12

PubMed: 31113472 ( click the link to review the publication )

Biomed Pharmacother, 2019, 115:108570

PubMed: 31054509 ( click the link to review the publication )
Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Cancer Biol Ther, 2019, 20(5):700-710

PubMed: 30571927 ( click the link to review the publication )

J Mol Endocrinol, 2019, 62(2):67-78

PubMed: 30481159 ( click the link to review the publication )

Dev Biol, 2019, 449(2):122-131

PubMed: 30826398 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):669-682

PubMed: 30849634 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(3):e0213186

PubMed: 30830950 ( click the link to review the publication )

Pain Res Manag, 2019, 2019:1648919

PubMed: 30809320 ( click the link to review the publication )

Oncotarget, 2019, 10(20):1903-1917

PubMed: 30956773 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 10.1016/j.jcmgh.2019.10.005

PubMed: 31654770 ( click the link to review the publication )

eNeuro, 2019, 6(1)

PubMed: 30783618 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Neuropsychopharmacology, 2018, 43(8):1779-1788

PubMed: 29760409 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):623

PubMed: 29795376 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1081

PubMed: 30349042 ( click the link to review the publication )

Arch Toxicol, 2018, 92(7):2227-2243

PubMed: 29845424 ( click the link to review the publication )

Basic Res Cardiol, 2018, 114(1):3

PubMed: 30446837 ( click the link to review the publication )

Oncoimmunology, 2018, 7(11):e1466018

PubMed: 30377559 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2013-2023

PubMed: 29934340 ( click the link to review the publication )
Biochim Biophys Acta Mol Basis Dis, 2018, 1864(8):2610-2622

PubMed: 29684588 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)

PubMed: 30424007 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):8492

PubMed: 29855565 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13638

PubMed: 30206377 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9391

PubMed: 29925922 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12886

PubMed: 30150730 ( click the link to review the publication )

Mol Pharmacol, 2018, 94(2):793-801

PubMed: 29880639 ( click the link to review the publication )

Biochem J, 2018, 475(24):3921-3932

PubMed: 30552170 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(1):65-75

PubMed: 29721849 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194661

PubMed: 29579087 ( click the link to review the publication )

J Med Virol, 2018, 90(9):1478-1485

PubMed: 29704439 ( click the link to review the publication )

Med Sci Monit, 2018, 24:2620-2630

PubMed: 29704392 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):1967-1974

PubMed: 30008890 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467324 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36413-36429

PubMed: 30559927 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )
Oncotarget, 2018, 9(39):25630-25646

PubMed: 29876013 ( click the link to review the publication )

Cond Med, 2018, 1(2):64-72

PubMed: 30135960 ( click the link to review the publication )

Oncotarget, 2018, 9(28):19597-19612

PubMed: 29731968 ( click the link to review the publication )

Oncotarget, 2018, 9(63):32182-32190

PubMed: 30181808 ( click the link to review the publication )

Data Brief, 2018, 17:1314-1319

PubMed: 29876485 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(11)E3539

PubMed: 30424007 ( click the link to review the publication )

Korean J Physiol Pharmacol, 2018, 22(1):23-33

PubMed: 29302209 ( click the link to review the publication )

JCI Insight, 2018, 3(4)95824

PubMed: 29467324 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2235-2248

PubMed: 28436940 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(51):E10981-E10990

PubMed: 29203668 ( click the link to review the publication )

Cell Rep, 2017, 19(4):875-889

PubMed: 28445736 ( click the link to review the publication )

Elife, 2017, 6e22767

PubMed: 28318487 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(21):3865-3880

PubMed: 28832971 ( click the link to review the publication )

J Med Chem, 2017, 60(13):5334-5348

PubMed: 28581289 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Front Immunol, 2017, 8:671

PubMed: 28659914 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(12):2689-2700

PubMed: 28802253 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2017, 6:54-65

PubMed: 28664166 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Virol, 2017, 91(16)

PubMed: 28566376 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12084

PubMed: 28935977 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8641

PubMed: 28819194 ( click the link to review the publication )

Mech Ageing Dev, 2017, 166:6-15

PubMed: 28843433 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

J Neuropathol Exp Neurol, 2017, 76(12):1000-1007

PubMed: 29136455 ( click the link to review the publication )

J Endocrinol, 2017, 233(3):369-379

PubMed: 28438776 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2017, 312(3):F502-F515

PubMed: 28052874 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Int J Mol Med, 2017, 40(3):661-672

PubMed: 28677722 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:3-10

PubMed: 27761809 ( click the link to review the publication )

Oncotarget, 2017, 8(69):114156-114172

PubMed: 29371976 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3172-3187

PubMed: 29423038 ( click the link to review the publication )
Oncotarget, 2017, 8(47):83155-83170

PubMed: 29137331 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4079-4095

PubMed: 27863422 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:375-385

PubMed: 27761836 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29371976 ( click the link to review the publication )

Sci Rep, 2017, 589:97-106

PubMed: 28273598 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Death Differ, 2016, 23(8):1312-21

PubMed: 26915294 ( click the link to review the publication )

Sci Signal, 2016, 9(422):ra34

PubMed: 27048565 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:62

PubMed: 27231489 ( click the link to review the publication )

Oncoimmunology, 2016, 5(11):e1219008

PubMed: 27999738 ( click the link to review the publication )

Oncoimmunology, 2016, 5(6):e1164919

PubMed: 27471639 ( click the link to review the publication )

Osteoarthritis Cartilage, 2016, 24(8):1451-60

PubMed: 27072078 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2432-2441

PubMed: 27474150 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(2):299-312

PubMed: 26772204 ( click the link to review the publication )

Pharmacol Res, 2016, 103:328-39

PubMed: 26657418 ( click the link to review the publication )

Transl Psychiatry, 2016, 6(12):e974

PubMed: 27922638 ( click the link to review the publication )

Dis Model Mech, 2016, 9(5):541-52

PubMed: 26989193 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )
J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Front Cell Neurosci, 2016, 10:221

PubMed: 27729849 ( click the link to review the publication )

Front Cell Neurosci, 2016, 9:510

PubMed: 26793062 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Mol Brain, 2016, 9(1):79

PubMed: 27535553 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

BMC Cancer, 2016, 10.1186/s12885-016-2353-7

PubMed: 27188282 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Biol Chem, 2016, 397(1):75-83

PubMed: 26431101 ( click the link to review the publication )

Methods Enzymol, 2016, 573:161-81

PubMed: 27372753 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep28025

PubMed: 27320682 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7390-402

PubMed: 26862729 ( click the link to review the publication )

Gene Regul Syst Bio, 2016, 10:9-13

PubMed: 26823649 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Blood, 2015, 5;125(6):941-8

PubMed: 25468569 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms7537

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:7023

PubMed: 25960197 ( click the link to review the publication )

Nat Commun, 2015, 6:6537

PubMed: 26055519 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(14):3230-3240

PubMed: 25813020 ( click the link to review the publication )
Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26701908 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

J Neurosci, 2015, 35(3):1250-9

PubMed: 25609639 ( click the link to review the publication )

Br J Cancer, 2015, 112(2):329-37

PubMed: 25514379 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: 25284154 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Toxicol Sci, 2015, 148(1):220-8

PubMed: 26251326 ( click the link to review the publication )

Sci Rep, 2015, 5:16873

PubMed: 26585834 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 10.1093/ijnp/pyv029

PubMed: 25762717 ( click the link to review the publication )

Front Neurosci, 2015, 9:319

PubMed: 26441495 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 151(2):281-94

PubMed: 25904215 ( click the link to review the publication )

Virology, 2015, 485:340-54

PubMed: 26331681 ( click the link to review the publication )

J Appl Physiol (1985), 2015, 119(4):342-51

PubMed: 26112243 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144660

PubMed: 26713848 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137699

PubMed: 26361334 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )
Future Virol, 2015, 10(4), 351–356

PubMed: ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25801-14

PubMed: 26317649 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Genes Dev, 2014, 28(14):1578-91

PubMed: 25030697 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Int J Cancer, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

Addict Biol, 2014, 10.1111/adb.12161.

PubMed: 25041570 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(1):32-7

PubMed: 24165483 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 7):1441-53

PubMed: 24463822 ( click the link to review the publication )

Eur J Immunol, 2014, 44(8):2478-88

PubMed: 24810486 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(3):415-27

PubMed: 24248598 ( click the link to review the publication )

Retrovirology, 2014, 11:67

PubMed: 25116364 ( click the link to review the publication )

Neuromolecular Med, 2014, 16(4):727-41

PubMed: 25063076 ( click the link to review the publication )

Pharmacological Reports, 2014, 49–55

PubMed: ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106784

PubMed: 25198282 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115401

PubMed: 25521755 ( click the link to review the publication )

Pharmacol Rep, 2014, 66(1):49-55

PubMed: 24905306 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4516-28

PubMed: 24980831 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(28):E2621-8

PubMed: 23788661 ( click the link to review the publication )

Genet Mol Biol, 2013, 36(3):299-307

PubMed: 24130434 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2076-86

PubMed: 23047626 ( click the link to review the publication )

J Neuroscience, 2013, 33(50):19664-76

PubMed: 24336730 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Stem Cells, 2013, 31(7):1434-45

PubMed: 23592435 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2078-87

PubMed: 23939379 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Neurochem, 2013, 129(3):509-15

PubMed: 24147654 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Infect Immun, 2013, 82(2):706-19

PubMed: 24478085 ( click the link to review the publication )

Mol Reprod Dev, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )
Pediatr Nephrol, 2013, 28(10):1909-21

PubMed: 23052657 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74930

PubMed: 24058639 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Exp Hematol, 2013, 41(1):113-23.e2

PubMed: 22989761 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(12):2600-9

PubMed: 23012246 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Immunol, 2012, 189(4):1792-9

PubMed: 22786766 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2012, 22(9):651-6

PubMed: 22341945 ( click the link to review the publication )

J Am Heart Assoc, 2012, 1(3):e000901

PubMed: 23130137 ( click the link to review the publication )

J Virol, 2012, 86(6):3073-87

PubMed: 22238308 ( click the link to review the publication )

Breast Cancer Res Treat, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41776

PubMed: 22848598 ( click the link to review the publication )

Biochem Biophys Res Commun, 2012, 428(1):121-6

PubMed: 23063976 ( click the link to review the publication )

Biomol Ther (Seoul), 2012, 20(1):81-8

PubMed: 24116279 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

J Thorac Oncol, 2011, 6(7):1152-61

PubMed: 21597390 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(49):19629-34

PubMed: 22106282 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 414(1):25-30

PubMed: 21925145 ( click the link to review the publication )

J Biomed Biotechnol, 2011, 2011:371832

PubMed: 21151613 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Mol Pain, 2010, 6:51

PubMed: 20822541 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )
PLoS One, 2010, 5(12):e14462

PubMed: 21283510 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC1 ^[2] (Cell-free assay)	HDAC3 ^[2] (Cell-free assay)
0.51 μM	1.7 μM

In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21^WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. ^[1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. ^[2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SCC-3	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHOzXGNKSzVyPUCuNFYyKM7:TR?=	M2XNZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
ALL-PO	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4DDUmlEPTB;MD6wOlM2PSEQvF2=	NE[yVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
697	NUDWOWdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn21TWM2OD1yLkC5PVc3KM7:TR?=	NFvZfoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H748	M1Habmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWHJR\|UxRTBwMUCzN\|Qh\|ryP	M1\TeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NKM-1	NEHGbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWTJR\|UxRTBwMUC5NVIh\|ryP	NE\HWpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ES1	M{f3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIP6c5JKSzVyPUCuNVEzPTVizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1963	NEjpbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYrJR\|UxRTBwMUG1O\|kh\|ryP	MkmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H1417	NULQPXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1roTWlEPTB;MD6xNlk4PCEQvF2=	NHXIPGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NEC8	NXfpO2VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NG\lXWNKSzVyPUCuNVM2OjdizszN	MkS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CRO-AP2	NEHGe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1n5TWlEPTB;MD6xOlg5QSEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
A3-KAW	NUmyV4hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2TLc2lEPTB;MD6xO\|YzPyEQvF2=	M2KwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SF539	NHnnUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2iydGlEPTB;MD6xPVU6OyEQvF2=	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NOS-1	NIHwUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXzJR\|UxRTBwMUm2NVkh\|ryP	NYnwNYU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	NGm4R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2HI[2lEPTB;MD6yNFEyOyEQvF2=	NXq0T5FtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
COR-L88	NYHDe49XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M17ETGlEPTB;MD6yNlk2QSEQvF2=	NEHwTZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYD1TGg4UUN3ME2wMlI1ODd7IN88US=>	NXO2dVhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KARPAS-45	NYLsUXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEH1coNKSzVyPUCuNlc5OzNizszN	MnHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
DSH1	M4\3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVrkTGc6UUN3ME2wMlI5PzB6IN88US=>	NXT1RZhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HT-144	M{f0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkH4TWM2OD1yLkOwNlU3KM7:TR?=	NV[yTWtQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ATN-1	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX7JR\|UxRTBwM{C1O\|Yh\|ryP	M4LvXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HEL	NHXp[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX3JR\|UxRTBwM{GzOFgh\|ryP	NHy0[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NB12	NVXKb5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEDoe4NKSzVyPUCuN\|E4PTZizszN	NVLHO25VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LU-139	M2PMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVfJR\|UxRTBwM{O1NUDPxE1?	M2jMclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NGXZ[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUnJR\|UxRTBwM{O3NVYh\|ryP	Mn3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MOLT-13	NHOxeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{LqNGlEPTB;MD6zN\|gyKM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SR	MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PPR2lEPTB;MD6zOFI3OSEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CMK	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnGwTWM2OD1yLkO1O\|I4KM7:TR?=	NVruWmdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ES8	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFrQUYdKSzVyPUCuN\|YxOjJizszN	Mm[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB647-SCLC	NETKfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFTOb4tKSzVyPUCuN\|Y4OyEQvF2=	NX;yVnVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TE-8	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTBwM{[5N\|Uh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BV-173	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIK2PYZKSzVyPUCuN\|cyOjFizszN	M4nxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
DEL	NVfRTHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX\NWI8zUUN3ME2wMlM4PDh5IN88US=>	MkjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ARH-77	M2DmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1TM[WlEPTB;MD6zPFE6OyEQvF2=	NF7JTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCCIT	NYT1W4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LTOWlEPTB;MD6zPFY1QSEQvF2=	NFTobGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-8402	NH3FOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXqOm5rUUN3ME2wMlM5PzBzIN88US=>	NFq3e4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MONO-MAC-6	M2jaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{OyVWlEPTB;MD6zPFc4PiEQvF2=	NYPNToozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SK-MM-2	M4XjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHmydmxKSzVyPUCuN\|k5PjhizszN	NVPRd3pPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CHP-126	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3y2R2lEPTB;MD60NFI{OSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
A101D	NFrCWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTBwNECzJO69VQ>?	Mo\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SCH	M4H1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYKzN5g1UUN3ME2wMlQxOzR{IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NMC-G1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYTJR\|UxRTBwNECzOlch\|ryP	NUPDNW5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H209	M4rWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1[xXmlEPTB;MD60NFYyOyEQvF2=	MnLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MOLT-16	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zjTGlEPTB;MD60NVAyPyEQvF2=	NFnTd4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RPMI-6666	M3i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGfGXnNKSzVyPUCuOFEyOiEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
OPM-2	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHvhd3dKSzVyPUCuOFE2OTNizszN	MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MRK-nu-1	M2fFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXPJR\|UxRTBwNEOxOVMh\|ryP	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
BC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF22O2NKSzVyPUCuOFM1ODNizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MHH-NB-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlX2TWM2OD1yLkSzOFU{KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
Ramos-2G6-4C10	NWrYT3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LlNmlEPTB;MD60N\|g6PyEQvF2=	NIHsOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LS-513	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml7sTWM2OD1yLkS0OVAyKM7:TR?=	NXTQS\|U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
K5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4XsfWlEPTB;MD60O\|AzPSEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HOP-62	NVPZVXhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoD0TWM2OD1yLkS4N\|U5KM7:TR?=	NVHqcppZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H187	NU\FTIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXLJR\|UxRTBwNEmyNlch\|ryP	Mmm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
BE-13	M1TyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2TaTmlEPTB;MD60PVY3OSEQvF2=	NVLrV3MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HC-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoK2TWM2OD1yLkWwOFc{KM7:TR?=	NYLXUJJwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ACN	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2\reGlEPTB;MD61NVAzQCEQvF2=	M13PNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCC1599	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWLJR\|UxRTBwNUG1O{DPxE1?	M2HSWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MV-4-11	NUnuWWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYjJR\|UxRTBwNUOwOFEh\|ryP	M17TeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LC-2-ad	MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX3JR\|UxRTBwNUO2OlMh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HL-60	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFG5VmtKSzVyPUCuOVQzPjFizszN	NUnUOoVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB17	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUTJR\|UxRTBwNUSzPEDPxE1?	M1Gzc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TE-1	M2XCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVfJR\|UxRTBwNUWzNFYh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H524	Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MX;JR\|UxRTBwNUW0NFEh\|ryP	MnG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MZ7-mel	NHO3TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTBwNU[xNFUh\|ryP	M1rnb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
L-363	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUPidpo2UUN3ME2wMlU3PjV5IN88US=>	NHLrWVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BL-41	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUnJR\|UxRTBwNU[4PFkh\|ryP	NULYcpJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LU-134-A	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2jG[GlEPTB;MD61O\|A4OyEQvF2=	NWjJTHdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SIG-M5	M3zuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NILtNWRKSzVyPUCuOVc5PDhizszN	NGe5NGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ONS-76	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVLJR\|UxRTBwNUiyOFIh\|ryP	MnP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
KARPAS-299	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NI\sbGdKSzVyPUCuOVg2ODRizszN	NHzmW2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
DU-4475	NIjUcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnKzTWM2OD1yLkW4O\|A{KM7:TR?=	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NB69	M2fCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWW0OY1LUUN3ME2wMlU6QDJ3IN88US=>	MnnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkjMTWM2OD1yLk[wO\|E6KM7:TR?=	NEXj[Hg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LU-165	NH;tbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHH1dY1KSzVyPUCuOlE5OTJizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LOUCY	NF3yN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkC1TWM2OD1yLk[zN\|Y1KM7:TR?=	NXjOUmhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H526	NF\ER29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFOxXo9KSzVyPUCuOlM2PDFizszN	M2\TVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KE-37	NEj4V\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml25TWM2OD1yLk[0Nlc3KM7:TR?=	NGXyUFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NALM-6	NXT3T29IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWXrNXVOUUN3ME2wMlY1QDZizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CW-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX;XWIw5UUN3ME2wMlY2Pzl2IN88US=>	MlvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SU-DHL-1	NUfjSIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYfJR\|UxRTBwNkW5OFch\|ryP	NFPpUmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NB13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1[zdGlEPTB;MD62OlgyPyEQvF2=	Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
QIMR-WIL	M{f1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHTzeW1KSzVyPUCuOlg{PDNizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ECC12	M1vjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVTaW41SUUN3ME2wMlcxODh4IN88US=>	M1rCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KALS-1	MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFjYfXNKSzVyPUCuO\|A1QTJizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
COR-L279	M{HLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1HPc2lEPTB;MD63NFk6PiEQvF2=	NX6zTXlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB14	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn22TWM2OD1yLkeyOlE4KM7:TR?=	MlvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CCRF-CEM	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEHZUJpKSzVyPUCuO\|Q3PjFizszN	M3nsU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SW954	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXfKe21FUUN3ME2wMlc2QTl7IN88US=>	NELaWVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
IST-SL1	NXnPVpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV3JR\|UxRTBwN{ezOFgh\|ryP	NWPLTnpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LAMA-84	NYC1[YZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2fVSWlEPTB;MD63O\|U3PyEQvF2=	MlnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
Daudi	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml;uTWM2OD1yLke3OlgyKM7:TR?=	MmXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
BC-3	NGDwbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIKzNXJKSzVyPUCuO\|g{ODhizszN	NUWyN4hpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HCC2998	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWXJR\|UxRTBwN{izOkDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H69	NIq0d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYfqbmJMUUN3ME2wMlgxOTR5IN88US=>	M321WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CPC-N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVTtd5Y4UUN3ME2wMlgxPTJ2IN88US=>	NGfMR489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NOMO-1	NEH1TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MW\JR\|UxRTBwOEGwPFQh\|ryP	NWPBfYVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CESS	NVjROFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXzJR\|UxRTBwOEGxPVch\|ryP	M4frNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LC4-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUDTfYNDUUN3ME2wMlg1ODB5IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BL-70	M2nKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3SycmlEPTB;MD64OVcxOiEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
ES4	NFTDN\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3fPWmlEPTB;MD64OVg3QCEQvF2=	M2XWSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCE-T	NHvFUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFzRU3lKSzVyPUCuPFcyPzFizszN	NWHZdnl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
JAR	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXnJR\|UxRTBwOEe4Nlch\|ryP	NUC2Nm1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ST486	NIrqWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWnnU3ZDUUN3ME2wMlg4QTF5IN88US=>	NHLMeIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KS-1	NYrKNYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYTJR\|UxRTBwOEiwPVYh\|ryP	M2\sb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
GDM-1	M1vKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYnJR\|UxRTBwOEi2PFch\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EHEB	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NI\seGFKSzVyPUCuPVI2QDVizszN	M2fKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	NYPJdVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{DFRmlEPTB;MD65N\|I5PCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GOTO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYnrblU3UUN3ME2wMlk2ODd4IN88US=>	MoLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LXF-289	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3vTWmlEPTB;MD65OVkxOSEQvF2=	NX62OIJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
ES6	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NETabIpKSzVyPUCuPVY1OzdizszN	MnzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
OS-RC-2	NHLRb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkPDTWM2OD1yLkm2PFMh\|ryP	NXzOOHFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
DMS-153	NEW2TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTBwOUe0Olkh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-PN-DW	MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlTiTWM2OD1yLkm3PFMyKM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HH	NYHoSmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M13hTmlEPTB;MD65PFk2QSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SH-4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYXkNVRLUUN3ME2xMlAzPDFizszN	M2nGflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MOLT-4	NFryZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYPW[4tuUUN3ME2xMlA{PDV2IN88US=>	MlvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TGW	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoD0TWM2OD1zLkC3Olc2KM7:TR?=	M4[zWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
L-540	M{fBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NILjepVKSzVyPUGuNVA3ODRizszN	M4\UT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
PF-382	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|UxRTFwMUG1NVMh\|ryP	M{XnS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LC-1F	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIn2No1KSzVyPUGuNVIxODdizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
OVCAR-4	NILUflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYHJR\|UxRTFwMUOxOlUh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
A4-Fuk	NG[yOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{[1SGlEPTB;MT6xOVM3PCEQvF2=	M3G3S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HCC2218	M1\Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{WxdmlEPTB;MT6xOlY1OSEQvF2=	NVPBUFVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HAL-01	NU\VOWpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWHuXIdkUUN3ME2xMlE3QTR\|IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
IST-MEL1	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1X2ZWlEPTB;MT6xO\|Y2QSEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H719	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFr5TVRKSzVyPUGuNVc5QThizszN	NIGzWGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EVSA-T	NEDtVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYPS[msxUUN3ME2xMlE5OTF2IN88US=>	NEnuXm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SK-NEP-1	M4\nXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkjYTWM2OD1zLkKwNlY3KM7:TR?=	M1XITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
OCUB-M	M3e3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnf2TWM2OD1zLkKxOFg6KM7:TR?=	Mk\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MEG-01	M{\zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3fkVWlEPTB;MT6yNlEyQCEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
no-10	NGDjU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NInKUmpKSzVyPUGuNlMyOTJizszN	MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MHH-CALL-2	NV;tXoJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3S2PGlEPTB;MT6yOFczOSEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-N-DZ	M3rVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGPwfllKSzVyPUGuNlQ4PzZizszN	NX;oPFNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SCLC-21H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NELXe5BKSzVyPUGuNlY1PzhizszN	NHO0cIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
CTV-1	NGPMfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnjITWM2OD1zLkK3OFI2KM7:TR?=	NW[4S3g3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB1	NVPEOGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M125WWlEPTB;MT6yO\|c{OiEQvF2=	NHe5cWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H64	M37hO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXHoSoU1UUN3ME2xMlI5PDZ{IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MDA-MB-134-VI	NX3ESIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1LwN2lEPTB;MT6yPFU4PyEQvF2=	NXywVG8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LB2241-RCC	NXrwV\|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXrDTplYUUN3ME2xMlI5PjZ\|IN88US=>	NUDoSmtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
8-MG-BA	NXKwTZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlH5TWM2OD1zLkK4PFY3KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LP-1	NYLtOJN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkLXTWM2OD1zLkK5PVQ4KM7:TR?=	NVfaNG9vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LS-411N	NUfEWmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXnJR\|UxRTFwM{C5PVgh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CAL-148	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVvJR\|UxRTFwM{K1OFIh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H2171	M3vB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1XGZmlEPTB;MT6zOFUxOiEQvF2=	NIHoOok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkDDTWM2OD1zLkO1N\|kh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H2107	NXLL[WxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmriTWM2OD1zLkO1PFg{KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BB30-HNC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4mzTGlEPTB;MT6zPFk4QCEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
K-562	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MluzTWM2OD1zLkO5NlE6KM7:TR?=	NHvjTYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
PSN1	NYO3XHRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkOzTWM2OD1zLkSyNlg4KM7:TR?=	NGS3dIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC2157	NYXMdoxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjTNo9KSzVyPUGuOFI3QTFizszN	NVvEOIlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SBC-1	M{TRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYfJR\|UxRTFwNEK3OFEh\|ryP	M4PIN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MC116	NG\1bpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIXMdGdKSzVyPUGuOFM3OTVizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
KARPAS-422	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{LvXmlEPTB;MT60OVM2QCEQvF2=	NHfXTHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
LB996-RCC	M2fsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1fUTGlEPTB;MT60O\|ExOyEQvF2=	M1XvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MSTO-211H	NV;DRXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1Oyc2lEPTB;MT60O\|k5PyEQvF2=	NWK4bJV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
BT-474	NHSyfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUj4S\|JJUUN3ME2xMlUyPzZ2IN88US=>	M2LIRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
A388	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFjpc3hKSzVyPUGuOVE6PDVizszN	NVi5d5A{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SJSA-1	NEK5TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGrUbnhKSzVyPUGuOVIzPiEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
COLO-829	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{DOS2lEPTB;MT61N\|U3PCEQvF2=	NU\TWnF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KM-H2	M2HHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXfJR\|UxRTFwNU[2O{DPxE1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GR-ST	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV\JR\|UxRTFwNU[4NkDPxE1?	M{i2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
RPMI-8866	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHsTWM2OD1zLk[wNVQ1KM7:TR?=	M3K2c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KG-1	M1jGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MULJR\|UxRTFwNkG5NFEh\|ryP	MnjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H82	NYHyOlloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUTDOYNDUUN3ME2xMlY{PDB4IN88US=>	MnvWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LB1047-RCC	NGD0UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVfJR\|UxRTFwNkO0OVkh\|ryP	M1LOelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
KM12	NIfjVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXXJR\|UxRTFwNkS3JO69VQ>?	NGflUWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NB5	MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzJR\|UxRTFwNkW2O\|ch\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HDLM-2	NEf5WpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXm3d5d3UUN3ME2xMlY5OjhzIN88US=>	NFHsfYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KU812	NGrBcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIDhZVhKSzVyPUGuOlk3ODVizszN	NUH2cWxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
DB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYfJR\|UxRTFwN{CzOVMh\|ryP	M{KwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	NXHNeog{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV\JR\|UxRTFwN{WyN\|Qh\|ryP	NVjFT5U{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KURAMOCHI	NG\NUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4nWeGlEPTB;MT63O\|IxPyEQvF2=	NISweXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ETK-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEXkXJhKSzVyPUGuO\|g5PzlizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SK-UT-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MY\JR\|UxRTFwN{mzPFgh\|ryP	M2r1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
HUTU-80	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYrrfVExUUN3ME2xMlc6PTB6IN88US=>	MoTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ES7	NFHFZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTFwOECzNFIh\|ryP	NU\MNoZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
SW872	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NInXTZhKSzVyPUGuPFE{QTVizszN	M2LrU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
TK10	NWG4dZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3mzWWlEPTB;MT64N\|ExQCEQvF2=	NUHRdlVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LB831-BLC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1\aSWlEPTB;MT64N\|U3OyEQvF2=	NVS3UoRyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TE-9	NX61S45GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEj2[YNKSzVyPUGuPFQ1OjJizszN	NXXFUppvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MLMA	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NW\pUnpZUUN3ME2xMlg5OjN2IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
D-542MG	NHL3OmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3TRZmlEPTB;MT64PVM4OyEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-16	NEjPNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIfTUFlKSzVyPUGuPVI4OiEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LOXIMVI	MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVf3bpVzUUN3ME2xMlk{OjhizszN	MljoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
GB-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1PlfmlEPTB;MT65N\|g3PiEQvF2=	NX[4[GVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
IST-SL2	NWPVUXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXTLe\|BzUUN3ME2yMlAxOjZ{IN88US=>	MlrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
LAN-6	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUDrUnFSUUN3ME2yMlAyQTZ4IN88US=>	M1ewNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H510A	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF;lbXlKSzVyPUKuNFQ2ODJizszN	NI\m[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1092	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmH1TWM2OD1{LkC1NVI1KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
HT	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmHXTWM2OD1{LkGwOFU1KM7:TR?=	NVHkTpFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
RL95-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFXqR5dKSzVyPUKuNVE1QDJizszN	NYfwV21kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H1355	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4HMbWlEPTB;Mj6xNVc6OiEQvF2=	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H720	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGrqN5pKSzVyPUKuNVY5PzNizszN	NIDycm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1522	NYLCZ25CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoTZTWM2OD1{LkKxO\|I{KM7:TR?=	M3\teVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	NYjKU3J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M32yb2lEPTB;Mj6yOlkxOiEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
DG-75	NEXuendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGfMbmRKSzVyPUKuNlcyPDhizszN	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
ML-2	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYLJR\|UxRTJwM{K4OVUh\|ryP	MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SF126	NGfKN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlnHTWM2OD1{LkOzNFk1KM7:TR?=	MoTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MPP-89	NVW5VnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MnXwTWM2OD1{LkOzNVQ2KM7:TR?=	MlrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H345	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYjJR\|UxRTJwM{OyO\|ch\|ryP	NYPWfXFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LS-123	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVjBd2pyUUN3ME2yMlM1QTN4IN88US=>	NUTMRmN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB10	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml64TWM2OD1{LkSxNFkzKM7:TR?=	M4flWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVPJR\|UxRTJwNEKyOlch\|ryP	M{m5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
CP66-MEL	NXHzcm04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkHwTWM2OD1{LkS3O\|ch\|ryP	Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
L-428	M2TWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1O3N2lEPTB;Mj60PFUzOSEQvF2=	NIjKcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
DMS-79	NGPUR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYiyVYhEUUN3ME2yMlU1OTB\|IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1882	M{jpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX;l[lZZUUN3ME2yMlY4PTZ{IN88US=>	NHGzNnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KGN	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVjJR\|UxRTJwN{[4O\|Yh\|ryP	M3jXNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-1	M1zLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlyyTWM2OD1{Lke3NFg{KM7:TR?=	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
U-266	M{LsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn\yTWM2OD1{Lki0PFI{KM7:TR?=	MlnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
COLO-320-HSR	NUHVVJJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWXJR\|UxRTJwOEW2OFEh\|ryP	NUHxZm85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KMOE-2	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWXJR\|UxRTJwOEe3NVEh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
BB49-HNC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWLJR\|UxRTJwOUK0PEDPxE1?	NYLYPWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
GI-1	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mk[zTWM2OD1{LkmyPVU4KM7:TR?=	NEjnOIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1304	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFzGZnhKSzVyPUOuNFA2OTFizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H2227	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF;PblZKSzVyPUOuNFIxPzlizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
U-87-MG	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXXJR\|UxRTNwMEO1NVMh\|ryP	M1:zPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H747	NHXXZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkLhTWM2OD1\|LkC1NlA3KM7:TR?=	NX6xd5huRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
CTB-1	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVraPIgxUUN3ME2zMlA2Ozd4IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
RPMI-8226	NWDiSJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV3W[W1lUUN3ME2zMlE1Ozd6IN88US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H2141	M1m2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjoTWM2OD1\|LkG2OVY3KM7:TR?=	MoHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
IST-MES1	M4jyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGC3N4FKSzVyPUOuNVgzPzlizszN	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TE-5	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXLJR\|UxRTNwMkGzOFIh\|ryP	MmLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
UACC-257	M33nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn\4TWM2OD1\|LkSzOlU6KM7:TR?=	NFL6Wmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
SK-N-FI	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3zxU2lEPTB;Mz60OVIzPyEQvF2=	NUWze5BuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
MFH-ino	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUfJR\|UxRTNwNE[1PFkh\|ryP	M1rKWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SF268	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRTNwNEixO\|Qh\|ryP	NInzVHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
TE-12	NYC3VopET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2LnWWlEPTB;Mz61NVY6QSEQvF2=	NXrjPW9LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB6	NWO1VY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYPjT3h4UUN3ME2zMlU2PTZ\|IN88US=>	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
DJM-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1jiUmlEPTB;Mz61PVg6QSEQvF2=	M1rLOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
MZ1-PC	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PjfGlEPTB;Mz62NVYzPCEQvF2=	M1TibVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
OCI-AML2	NVP6bmlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MljETWM2OD1\|Lk[yOlcyKM7:TR?=	NWDIcnJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-H1155	MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX;5R5FuUUN3ME2zMlcxQTR5IN88US=>	NEDzTGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RKO	NGDMNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml2zTWM2OD1\|Lke3NVg6KM7:TR?=	NGrENGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ECC4	M2LW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mom4TWM2OD1\|Lkm3NVk2KM7:TR?=	NEC3RXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
BB65-RCC	NXu5enBqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGHw[Y1KSzVyPUOuPVc2PDdizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EB-3	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXXBSZhIUUN3ME2zMlk6PjN\|IN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SHP-77	M4j6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmPSTWM2OD12LkCwOVI1KM7:TR?=	MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H2196	NEjTUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEftTFhKSzVyPUSuNFU3OjVizszN	NGLSfGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
GI-ME-N	NUPRNm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX;Z[WJDUUN3ME20MlA3Ozl7IN88US=>	NG[2b2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
MN-60	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHjWUJJKSzVyPUSuNVA5PyEQvF2=	NHTLO2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1694	NH3MdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2KzemlEPTB;ND6xN\|QxPSEQvF2=	NUPRcIozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
LU-65	NV;1U3YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4HPWmlEPTB;ND6xOVM{OiEQvF2=	MkLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H1436	NWfuOXdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2jxVWlEPTB;ND6xPFM{OyEQvF2=	NX3oNJQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KINGS-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUXOZo1EUUN3ME20MlMyPDN{IN88US=>	M2nrOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
GT3TKB	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MY\JR\|UxRTRwM{OyOlgh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
Becker	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlrZTWM2OD12LkO3N\|EzKM7:TR?=	NHjLc3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
HCC1187	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkjHTWM2OD12Lki5OlU4KM7:TR?=	NX\3[\|V7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-502MG	NIrT[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWLKUmQ{UUN3ME21MlAxPDF4IN88US=>	NIjVUpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	M1P0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3q4PGlEPTB;NT6xN\|c4QCEQvF2=	NVG3[WxtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NB7	M1XpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYjhdGo3UUN3ME21MlE1OTF{IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SW962	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFnxdGVKSzVyPUWuN\|g5OTRizszN	M{LFUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
no-11	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUficpM1UUN3ME21Mlc3OzR\|IN88US=>	NXLwfXdvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
KNS-81-FD	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4H4XGlEPTB;NT65NFY6PCEQvF2=	Ml;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
COLO-684	NVHaXnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn2zTWM2OD13Lkm5OFk1KM7:TR?=	NWewXnlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
D-263MG	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXHJR\|UxRTZwMEi4PVUh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-24	NH\qOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{fKO2lEPTB;Nj6yPFUyKM7:TR?=	NWHEeXhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TE-10	M1\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjITWM2OD14LkSyOlI{KM7:TR?=	NHOzcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EKVX	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlPjTWM2OD14LkS2N\|IyKM7:TR?=	Mn3xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H1648	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUjudopjUUN3ME22MlY4PTV5IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LB771-HNC	NGLLSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTZwOUKzNFEh\|ryP	M2HsbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	NYDiTGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfJR\|UxRThwMUOxOlYh\|ryP	NXPDT5VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
COLO-668	MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{DaZWlEPTB;OD6yO\|c5PiEQvF2=	NHvtOlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
EW-12	NGK0XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{PScGlEPTB;OD60NFgxOyEQvF2=	NUnISGc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
A253	NHLHRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRThwOES2OlEh\|ryP	M3XQTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
NCI-H2126	NV7rU2RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWexSIIyUUN3ME24Mlg6OzF7IN88US=>	MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
Calu-6	NHPuVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIDwWJRKSzVyPUiuPVkxPDJizszN	NHrM[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H23	M1zBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NU\Fd2NpUUN3ME25MlE4PzR4IN88US=>	M3L5XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
WSU-NHL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoHjTWM2OD17Lke3OFc5KM7:TR?=	MnzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
MMAC-SF	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{W3XmlEPTB;OT65O\|kxPCEQvF2=	MljxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
SK-LMS-1	NWTXb5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWe5SIJZUUN3ME2xNE4zQDN2IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
GCIY	M4fBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEnvRm1KSzVyPUGwMlU6OjRizszN	MnvEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
TE-15	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXPlVlVJUUN3ME2xNU43ODB2IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EoL-1-cell	M4nJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX7JR\|UxRTFzLke2PFIh\|ryP	Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H2081	NEDoO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYTJR\|UxRTFzLke3PFYh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{XZWGlEPTB;MUKuNlQ3OyEQvF2=	MofJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
CAS-1	M3fpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmXlTWM2OD1zMj6zOlMyKM7:TR?=	NFKyVm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
C2BBe1	NFLLbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWTLRYlQUUN3ME2xNk43OTNzIN88US=>	NGPVTlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
D-247MG	M3\uPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfR[mZTUUN3ME2xNk44QTV{IN88US=>	MnPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-SNU-5	NVvvTnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoraTWM2OD1zMj64NFE{KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
LS-1034	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF3hNo5KSzVyPUG0MlM6PzVizszN	M2PQdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
EW-18	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVzJR\|VkUUN3ME2xOE41PDhizszN	MojIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
Raji	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NESxXpdKSzVyPUG0MlUxPDlizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
D-283MED	NYTBSoR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{TQPGlEPTB;MUSuOlI4OSEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
MZ2-MEL	M3HUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV;JR\|UxRTF2Lkm2PVYh\|ryP	NHLlUVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-SNU-16	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXrJR\|UxRTF3LkS2N\|Mh\|ryP	NH7McFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
P30-OHK	NYDJdFVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2nvXmlEPTB;MUeuO\|g{OSEQvF2=	NFn3N2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
RXF393	M{fFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUnPc2l3UUN3ME2xPU4xOTh4IN88US=>	NH\4Xmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
NCI-H1395	NI\EbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml22TWM2OD1{MD62O\|A{KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
U-698-M	NXj6NFhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFHlR5lKSzVyPUKwMlcxPzVizszN	NXzvZ4EyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
NCI-SNU-1	M1n1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2Lab2lEPTB;MkCuO\|IzOyEQvF2=	M1;wN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4PzV7Lze+V2FPT0WUPD;hQi=>
SW684	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PRVWlEPTB;MkGuNVcyPiEQvF2=	MnLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H716	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIq4d45KSzVyPUKxMlMyPTRizszN	NWf0TYRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
JVM-2	NX;qXGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVrJR\|UxRTJzLkSxN\|Mh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
NCI-H1581	NXTKNGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPJR\|UxRTJ{LkSxOFgh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
CA46	NGfiOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NY\Pb29uUUN3ME2zNU43QTN4IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
SNB75	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGXvTIdKSzVyPUOzMlY2ODNizszN	NGS2cIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
KNS-42	M2fUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYTLfYhoUUN3ME2zOU46PjJ2IN88US=>	NUCzSY5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
TUR	NU\SOIlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVzJR\|UxRTN4LkC1NlEh\|ryP	NHnRWXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
REH	NV:3[GRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MofSTWM2OD1\|Nz64NlEyKM7:TR?=	MkXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
EW-22	M{L3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXXJR\|UxRTR{LkK4PFUh\|ryP	MlLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
NCI-H446	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGPZZWhKSzVyPUSyMlc5PTNizszN	NIPkNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzd3OT:nQnNCVkeHUkyvZV4>
ES3	Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4XzV2lEPTB;NEOuNVM{QSEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|c2QS9pPmPBUmdGWjxxYU6=
EW-11	NH\XXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHrJOGVKSzVyPUS0MlgzOThizszN	MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlc4PTlxJ{7TRW5ITVJ:L3G+
RH-1	M12ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX\JR\|UxRTR5LkW4NVIh\|ryP	NVGyNlc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd5NUmvK\|5USU6JRWK8M4E,
HepG2	MkLRSpVv[3Srb36gZZN{[Xl?			MXrJcohq[mm2aX;uJI9nKGi3bXHuJGhmeEd{IHPlcIx{NCCLQ{WwJF0hOC5yMEC5JO69VS5?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
HCT116	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M372[lQ5KGi{cx?=	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	NETHe2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkewOVAzOid-MkK3NFUxOjJ:L3G+
A549	MmHXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MU[0PEBpenN?	M3XrPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	Mo\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MEWwNlIoRjJ{N{C1NFIzRC:jPh?=
HEK293	NVjv[JJTTnWwY4Tpc44h[XO\|YYm=			M3L1PGlvcGmkaYTpc44hd2ZiaIXtZY4hSy22ZYLtbY5idCCITFHHMZRi\2enZDDISGFEOSCrbjDISWszQTNiY3XscJMtKEmFNUCgQUAxNjF{IN88UU4>	MoDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2NEG4OFYoRjF7NESxPFQ3RC:jPh?=
HEK293	MYLGeY5kfGmxbjDhd5NigQ>?			M2HETGlvcGmkaYTpc44hd2ZiSFTBR\|EhcW5iSFXLNlk{KGOnbHzzMEBKSzVyIE2gNE4yOiEQvF2u	MlPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEi1OlMoRjF6M{C4OVY{RC:jPh?=
SNU16	MVfGeY5kfGmxbjDhd5NigQ>?			M1naN2lvcGmkaYTpc44hd2ZiSFTBR{Bnem:vIHj1cYFvKFOQVUG2JINmdGy\|LDDJR\|UxKD1iMD6yN\|Mh\|ryPLh?=	NY\Z[21DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HEK293	MkG1SpVv[3Srb36gZZN{[Xl?			MUHJcohq[mm2aX;uJI9nKGi3bXHuJGMufGW{bXnuZYwhTkyDRz30ZYdo\WRiSFTBR\|IhcW5iSFXLNlk{KGOnbHzzMEBKSzVyIE2gNE4zPSEQvF2u	NYLOSlJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
U937	NV33eVJxTnWwY4Tpc44h[XO\|YYm=			MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIHnuJHU6OzdiY3XscJMh[nliaX3teY5weHKnY3nwbZRifGmxbjDhd5NigSxiSVO1NEA:KDBwMzFOwG0v	MnvpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|OEGyN\|goRjF6M{ixNlM5RC:jPh?=
SK-N-BE(2)	M2S5NWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYG0PEBpenN?	NHvBemdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uSkVqMjmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{Og{txONg>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
AGS	NWX3SWRSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3rjN\|czKGi{cx?=	NHPuXG5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFHHV{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6zOEDPxE1w	M4HiWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
MCF7	NHvPN5VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1fnXlQ5KGi{cx?=	MmTVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IITy[YF1\WRiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBz\W[{ZYPo[YQh\X[ncomgPVYhcHK\|IH3lZZN2emWmIH;uJIRigSBzMDDifUBNd3e{eTDhd5NigSxiSVO1NEA:KDBwM{Wg{txONg>?	M1zOZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkGzOlM2Lz5{Nk[xN\|Y{PTxxYU6=
HEK293	M1PmeWZ2dmO2aX;uJIF{e2G7			NVLhOY9jUW6qaXLpeIlwdiCxZjDoeY1idiCFLYTldo1qdmGuIF\MRWcufGGpZ3XkJGhFSUN\|IHnuJGhGUzJ7MzDj[YxteyxiSVO1NEA:KDBwNDFOwG0v	M3fBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NESxPFQ3Lz5zOUS0NVg1PjxxYU6=
HEK293	MlXmSpVv[3Srb36gZZN{[Xl?			Mmq0TY5pcWKrdHnvckBw\iCKRFHDN{BqdiCKRVuyPVMh[2WubIOsJGlEPTBiPTCwMlQh\|ryPLh?=	MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEi1OlMoRjF6M{C4OVY{RC:jPh?=
HEL	MYnGeY5kfGmxbjDhd5NigQ>?		NFTSZZI{KGi{cx?=	NUf0eXduUW6qaXLpeIlwdiCxZjDjcIF{eyBzIFjERWMhcW5iSFXMJINmdGy\|IIXzbY5oKEKxYz3MfZMhMGGlZYT5cEkuSU2FIHHzJJN2[nO2cnH0[UBxemWrbnP1ZoF1\WRiZn;yJFMhcHK\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlQ{KM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
PC3	M{XYcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUW0PEBpenN?	MljpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOC52MzFOwG0v	MmHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OUWxOVAoRjJ6M{m1NVUxRC:jPh?=
HEL	NVW5bmlHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUm3NkBpenN?	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiHTDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC52NDFOwG0v	MoTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5OEeyOlIoRjJ7N{i3NlYzRC:jPh?=
MOLT4	M3HuUmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHnoVnY4OiCqcoO=	NHzwW2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlQ2KM7:TT6=	NHrYOXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe4O\|I3Oid-Mkm3PFczPjJ:L3G+
HCT116	NWHCOFA3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NIPVfmg4OiCqcoO=	MljmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE41PyEQvF2u	NYHkWZA3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI{QTdpPkK5NlAzOzl5PD;hQi=>
HEL	NFToeXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUS0PEBpenN?	MmH0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDISWwh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFgh\|ryPLh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
HCT116	NULMTG52TnWwY4Tpc44h[XO\|YYm=			NFn5fHRKdmirYnn0bY9vKG:oIHj1cYFvKEiFVEGxOkBk\WyuczygTWM2OCB;IECuOUDPxE1w	Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
U937	NH\IPFlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVjUNHJzPzJiaILz	NHHMd2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW5N\|ch[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD61OUDPxE1w	M2P2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUWzO\|IzLz5{NUm1N\|czOjxxYU6=
U937	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUnqcohPPzJiaILz	NUm0TpROSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIgh[W[2ZYKgO\|IhcHK\|IHL5JG1VXC2kYYPl[EBie3OjeTygTWM2OCB;IECuOVUh\|ryPLh?=	M3\HUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe0N\|I3Lz5{NUi3OFMzPjxxYU6=
HCT116	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV[yJIRigXN?	MULHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNkBl[Xm\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvPiEQvF2u	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUO5OEc,OjJ3NEGzPVQ9N2F-
HL60	Mk[wSpVv[3Srb36gZZN{[Xl?		NFjRemQ{KGi{cx?=	MUXJcohq[mm2aX;uJI9nKGOuYYPzJFEhUESDQzDpckBpfW2jbjDIUFYxKGOnbHzzJJV{cW6pIFLvZ{1C[y2OeYOtRW1EKGG\|IIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDNiaILzJIZwdGyxd3XkJIJ6KHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA{KGi{czDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjZ{IN88UU4>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
MOLT4	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVu0PEBpenN?	NX7ze3dYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE43PSEQvF2u	NFzQNWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWxNVkxPid-Mki1NVE6ODZ:L3G+
HCT116	M3H6VGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MlfCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTBiPTCwMlY4KM7:TT6=	NUnESXhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OFI1QTZpPkKxO\|QzPDl4PD;hQi=>
HCT116	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NHPCNYFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiSVO1NEA:KDBwNkeg{txONg>?	MonTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NUCyNlEoRjJzNkWwNlIyRC:jPh?=
HCT116	Mn;lRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXO3NkBpenN?	NV6wRoQxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQOVMh\XiycnXzd4lv\yCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHPlcIx1cXSncj3icJVmKGOnbHygeoli[mmuaYT5JIF{e2G7LDDDR\|UxKD1iMD63JO69VS5?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
HCT116	M2\oU2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			M4HX[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIJ6KEOnbHzUbZRmei2EbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC55IN88UU4>	M{nwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{ewN\|c{Lz5zOEO3NFM4OzxxYU6=
HEK293T	NVG2cXduTnWwY4Tpc44h[XO\|YYm=		MmLRNUBpeg>?	NY\NemFvUW6qaXLpeIlwdiCxZjDGUGFINXSjZ3fl[EBJTEGFMjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy\|IIXzbY5oKGGlZYT5cIF1\WRibInzbY5mKHOrZHWgZ4hicW5iYYOgd5Vje3S{YYTlJIFnfGW{IEGgbJIh[nliY3;sc5JqdWW2cnnjJIRmfGWldHnvckBj[XOnZDDhd5NigSxiSVO1NEA:KDBwN{Sg{txONg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OUi4OUc,Ojl{OEm4PFU9N2F-
ML1	M2\pbWFvfGm2dX3vdkBie3OjeR?=			NULielB2SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgUWwyKGOnbHzzMEBKSzVyIE2gNE44PSEQvF2u	NVnqSGxGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|Q2OzRpPkG5OVM1PTN2PD;hQi=>
HCT116	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MXqzJIRigXN?	NHX4O\|lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjCzJIRigXNiYomgW3NVNTFiYYPzZZktKEmFNUCgQUAxNjd4IN88UU4>	M{nndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{KxNlE2Lz5{MkOyNVIyPTxxYU6=
U937	NGPsZWNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWq0PEBpenN?	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV7M{egZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwN{eg{txONg>?	NYTVVJhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
HCT116	MmTHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml3RO\|IhcHK\|	NFG0NmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czDifUBOXFRvYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlc5KM7:TT6=	NXPM[ppzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|Q{OjZpPkK1PFc1OzJ4PD;hQi=>
K562	NVr6WZlqTnWwY4Tpc44h[XO\|YYm=		MVOxNEBucW6\|	M4nMNGlvcGmkaYTpc44hd2ZiS1TBR\|MhcW5iaIXtZY4hUzV4MjDj[YxteyC3c3nu[{BcO0ifYXPleJlt[XSnZDDobZN1d26nIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEGwJI1qdnNiYomgcIlyfWmmIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE44QSEQvF2u	NFr1NXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[4NVQxPCd-Mk[2PFE1ODR:L3G+
HCT116	NEnEZZlEgXSxdH;4bYNqfHliYYPzZZk>		MX:zJIRigXN?	NFXJOndEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFeVVD2xJIF{e2G7LDDJR\|UxKD1iMD64JO69VS5?	NF71XG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES1NlIzPid-MkC0OVIzOjZ:L3G+
SKBR3	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			M2TMRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vCVlMh[2WubIOsJGlEPTBiPTCwMlg4KM7:TT6=	MmfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OVQoRjF6MkS3OVU1RC:jPh?=
Sf9	MUDGeY5kfGmxbjDhd5NigQ>?		M{fCclMhcHK\|	MYHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFOteIVzdWmwYXygTIl{NXSjZ3fl[EBJTEGFMUGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKEGlLVHy[{1IdHlvTInzLGFkMS2DTVOgZZMhe3Wkc4TyZZRmKHC{ZYTy[YF1\WRiZn;yJFMhcHK\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBi\nSncjCzNEBucW6\|IHL5JIZtfW:{b33leJJq[yCvZYToc4QtKEmFNUCgQUAxNjlizszNMi=>	MoDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MEG1NVQoRjJ6NUCxOVE1RC:jPh?=
S2	NFzKOWlHfW6ldHnvckBie3OjeR?=			NFrEOHhKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO\|ZXSgbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV\|Ih[2WubIOsJGlEPTBiPTCwMlk1KM7:TT6=	NHzKNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOxO\|Q2OCd-MUmzNVc1PTB:L3G+
HEK293T	NYDoUFh4TnWwY4Tpc44h[XO\|YYm=		NFzBNYMyKGi{	MnK2TY5pcWKrdHnvckBw\iCqdX3hckBHVEGJLYTh[4dm\CCKRFHDNUBmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{B2e2mwZzDhZ4V1gWyjdHXkJIx6e2mwZTDzbYRmKGOqYXnuJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JINwdG:{aX3leJJq[yCmZYTlZ5Rqd25iYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlA4KM7:TT6=	M3PXS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki5PFg2Lz5{OUK4PVg5PTxxYU6=
A549	NUCwb4dlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2fKdFczKGi{cx?=	M3vURWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUEWzJIV5eHKnc4PpcochSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2WubITpeIVzNWKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEOFNUCgQUAyNjJizszNMi=>	NWfuc4lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OFE5PDZpPkG5OFQyQDR4PD;hQi=>
A549	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NGL1elJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZpkhS2WubGTpeIVzNUKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjJizszNMi=>	NXiwR481RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
HEK293T	NVS5SVEzTnWwY4Tpc44h[XO\|YYm=		M3LCN\|EhcHJ?	NXnOR3RGUW6qaXLpeIlwdiCxZjDoeY1idiCITFHHMZRi\2enZDDISGFEOyCneIDy[ZN{\WRiaX6gTGVMOjl\|VDDj[YxteyC3c3nu[{Bi[2W2eXzheIVlKGy7c3nu[UB{cWSnIHPoZYlvKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KGOxbH;ybY1mfHKrYzDk[ZRm[3Srb36gZoF{\WRiYYPzZZktKEmFNUCgQUAyNjJ\|IN88UU4>	MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEm4PFUoRjJ7Mki5PFg2RC:jPh?=
HEL	NHfTdZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4\WbFQ5KGi{cx?=	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFjFUEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT6yPUDPxE1w	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
G401	MknMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGPpfYk4OiCqcoO=	NVzIU3dYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHOFAyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDj[YxtfGm2ZYKtZox2\SClZXzsJJZq[WKrbHn0fUBie3OjeTygR2M2OCB;IEGuN{DPxE1w	NFGyUYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS0NVg1Pid-MUm0OFE5PDZ:L3G+
G401	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NH2yVlVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFe0NFEh[2WubIOgZpkhS2WubGTpeIVzNUKudXWgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjNizszNMi=>	NWrSZ\|U2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
Sf9	M4HpS2Z2dmO2aX;uJIF{e2G7		NFHXTXk{KGi{cx?=	NVfUWWlOUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBENXSncn3pcoFtKEircz30ZYdo\WRiSFTBR\|EyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSClZXzsd{B2e2mwZzDBZ{1CemdvR3z5MWx6eyiDYzmtRW1EKGG\|IIP1ZpN1emG2ZTDwdoV1emWjdHXkJIZweiB\|IHjyd{Bnd2yub4fl[EBjgSC\|dXLzeJJifGViYXTkbZRqd25iYX\0[ZIhOzBibXnud{BqdiCycnXz[Y5k\SCxZjCwMlIhfU1iU1HIRUBjgSCoLDDJR\|UxKD1iMT6zJO69VS5?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVyMUWxOEc,Ojh3MEG1NVQ9N2F-
K562	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUK0PEBpenN?	NV;H[IVuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxMlMzKM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDVzMUmwOkc,Ojh3MUG5NFY9N2F-
Huh7	MoK5RY51cX[rcnHsJIF{e2G7		NHjsfIY{KGSjeYO=	MX7BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDIR3Yh\2Wwb4T5dIUhOWJiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{Bk\WyuczDh[pRmeiB\|IHThfZMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5MEBGSzVyIE2gNU41KM7:TT6=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MEewNEc,OjV2OUC3NFA9N2F-
MDA-MB-231	NEfxWFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFTYUmI1QCCqcoO=	M3\4O2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAyNjRzIN88UU4>	MnP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OUWxOVAoRjJ6M{m1NVUxRC:jPh?=
K562	MXTGeY5kfGmxbjDhd5NigQ>?		NYjSSWliOTBibXnudy=>	MWjJcohq[mm2aX;uJI9nKEuGQVOxJIlvKGi3bXHuJGs2PjJiY3XscJMhfXOrbnegX\|NJZWGlZYT5cIF1\WRiaHnzeI9v\SCjczDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiBzMDDtbY5{KGK7IHzpdZVq\CC\|Y3nueIltdGG2aX;uJINwfW62aX7nJI1mfGixZDygTWM2OCB;IEGuOFgh\|ryPLh?=	M{TzVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkixOFA1Lz5{Nk[4NVQxPDxxYU6=
HL60	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWK0PEBpenN?	NIjEcYxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOVIh\|ryPLh?=	NYPIPVExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
HeLa	NWDsXoc5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NE\pe5VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhmVGFiY3XscJMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVAhRSBzLkW4OFg6KM7:TT6=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyNkO3NEc,OTd4ME[zO\|A9N2F-
HeLa	NVzVXYZGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M17GflczKGi{cx?=	NXrNflRKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFEvPiEQvF2u	M4TrNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyN\|k4Lz5{OUKwNlM6PzxxYU6=
K562	M3TMcGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MU[0PEBpenN?	NEnPVIRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFu1OlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuOlgh\|ryPLh?=	M1zIdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEG1NFA6Lz5{OESxOVAxQTxxYU6=
HeLa	NEnpfnJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NF7lZVY4OiCqcoO=	NYHwfHo1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQOVMu\GWoaXPp[Y51KEinTHGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHz0bZRmei2kbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCFQ{WwJF0hOS56IN88UU4>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
HeLa	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEinTHGgZ4VtdHNiYomgR4VtdFSrdHXyMWJtfWViY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlgh\|ryPLh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN5MEO3N{c,OTh\|N{CzO\|M9N2F-
HCT116	MUDGeY5kfGmxbjDhd5NigQ>?		NVv6TIpkOThiaILz	MUTJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KHW\|aX7nJGJw[y2OeYOgLIVxe2mub36tRYMqNUGPQzDhd{B{fWK\|dILheIUheHKndILlZZRm\CCob4KgNVghcHK\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBi\nSncjCzJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCxMlk3KM7:TT6=	M2DMNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
DU145	NIPn[4pEgXSxdH;4bYNqfHliYYPzZZk>			NX3VNFNKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNkDPxE1w	NV\RfJhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxN\|EzPDhpPkG5NVMyOjR6PD;hQi=>
K562	MYfGeY5kfGmxbjDhd5NigQ>?			NH75Om9KdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTDwdoVx[XKnZDDmdo9uKEt3NkKg[ZJ6fGi{b3zleYtmdWmjIHPlcIx{NixiSVO1NEA:KDJizszNMi=>	MmTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2MUmzPFAoRjF{NEG5N\|gxRC:jPh?=
K562	MWjGeY5kfGmxbjDhd5NigQ>?			NEnHflhKdmirYnn0c5J6KGGldHn2bZR6KGGpYXnud5QhUGm\|dH;u[UBl\WGlZYT5cIF{\SBqSFTBR{khcW5iSzC1OlIh\XK7dHjyc4xmfWunbXnhJINmdGy\|LDDJR\|UxKD1iMjFOwG0v	M4HBOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUmyOFc{Lz5zNEW5NlQ4OzxxYU6=
HCT116	M2\T[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1PUdFQ5KGi{cx?=	NH61NHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNk4xOyEQvF2u	Mki4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NEC0NVMoRjJ6M{SwOFE{RC:jPh?=
HCT116	NYizW41SSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVy0PEBpenN?	NVnPelk4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvODdizszNMi=>	NVHGOYtWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NVUxODlpPkK4OFE2ODB7PD;hQi=>
NCI-H661	M1\wcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn[2O\|IhcHK\|	MmHORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFY3OSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxiZ4Lve5RpKGGodHXyJFczKGi{czDifUBOXFRvYnHz[YQh[XO\|YYmsJGlEPTBiPTCyMlE6KM7:TT6=	NH7keZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3OFMzPid-MkW4O\|Q{OjZ:L3G+
NCI-H661	NV;VPFNMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVm3NkBpenN?	NF\HV3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPjZzIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvOTlizszNMi=>	NFjQNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm1N\|czOid-MkW5OVM4OjJ:L3G+
SNU-16	MXjGeY5kfGmxbjDhd5NigQ>?			NVG2dWpWUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKG[{b32gV25WNTF4IDjoeY1idiCpYYP0dolkKGGmZX7vZ4Fz[2mwb33hLUBk\WyuczygTWM2OCB;IEKuNVk1PTlizszNMi=>	M3zPeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2Nk[3NlI4Lz5zNE[2O\|IzPzxxYU6=
Sf9	Ml;DSpVv[3Srb36gZZN{[Xl?		MUWxO{BpenN?	MoK0TY5pcWKrdHnvckBw\iCKaYO2MZRi\2enZDDISGFEOy:VTWLUJEg{QTVidH:gOFg6KHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGOxLXX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcochME[DTTmtcIFj\WynZDDhZ4V1gWyjdHXkJJBmeHSrZHWgd5Vje3S{YYTlJIFnfGW{IEG3JIhzeyCkeTDjZYxqeGW{IH3pZ5Jw\my3aXTpZ{Bud2KrbHn0fUB{cGmodDDhd5NigSxiSVO1NEA:KDJwM{GyNFYh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF5OUe0PUc,OzBzN{m3OFk9N2F-
ACHN	M{fq[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVS3NkBpenN?	Mn3oRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDQ1jOJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{LkSg{txONg>?	NHLWSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe4O\|I3Oid-Mkm3PFczPjJ:L3G+
SGC7901	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVnhWohuPzJiaILz	NVzrTW1pT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0eFN{mwNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCZU2Sg[JlmKHKnZIXjeIlwdiCjc4PhfUwhT0l7MDC9JFIvPSEQvF2u	NXTON\|ZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlE{PzZpPkKzNFYyOzd4PD;hQi=>
MDA-MB-231	NHn2WFZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3LORlczKGi{cx?=	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFIvPTVizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd6N{K2Nkc,Ojl5OEeyOlI9N2F-
MDA-MB-231	MV\BcpRq[2GwY3XyJIF{e2G7		M4jJR\|czKGi{cx?=	NHvt[IlCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTUA:KDJwODFOwG0v	NVP4UIhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OFE5OzRpPkKxO\|QyQDN2PD;hQi=>
A2780	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYe3NkBpenN?	M{fVNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUK3PFAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHPlcIx1cXSncj3icJVmKGOnbHygeoli[mmuaYT5JIF{e2G7LDDDR\|UxKD1iMzFOwG0v	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR2MUi0Okc,OTl2NEG4OFY9N2F-
A2780	NFq2NohCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NEP4O2hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJIJ6KEOnbHzUbZRmei2EbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOyEQvF2u	NVXScYxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUizO\|A{PzNpPkG4N\|cxOzd\|PD;hQi=>
HCT116	MVzBcpRq[2GwY3XyJIF{e2G7		M1i3U\|czKGi{cx?=	Mmr6RY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUSB;IEOuNUDPxE1w	M4DCTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{SxPFM1Lz5{MUe0NVg{PDxxYU6=
HT-29	MnjCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYe3NkBpenN?	MnG5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz6xJO69VS5?	M3LXT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
A549	MoLzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHLVVHI1QCCqcoO=	M1W1O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz6xNUDPxE1w	NH24NY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
A549	M2nl[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		NV\ZSmJ4PzJiaILz	NXrQWndyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy5zM{Sg{txONg>?	MlGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEC5OlEoRjJ4MUSwPVYyRC:jPh?=
A2780	M1\Ue2Z2dmO2aX;uJIF{e2G7		MV6xPEBpenN?	MUXJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gRVI4QDBiY3XscJMhfXOrbnegRo9kNUy7czCo[ZB{cWyxbj3BZ{kuSU2FIHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxPEBpenNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IEOuNVUh\|ryPLh?=	NVjyR3lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOFA1OTNpPkK4N\|QxPDF\|PD;hQi=>
SW620	MVLGeY5kfGmxbjDhd5NigQ>?			MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNYPjJyIHPlcIx{NCCLQ{WwJF0hOy5{IN88UU4>	NUDhXncyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PTRpPkG4NlQ4PTV2PD;hQi=>
HeLa	NXHjZVlUTnWwY4Tpc44h[XO\|YYm=		NFzDPHE{OCCvaX7z	MVjJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNiaX6gTIVN[SClZXzsd{Bi\nSncjCzNEBucW6\|IHL5JGZtfW:{IHTlJGx6eyCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSB\|LkKg{txONg>?	M3PGc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi5N\|Q{Lz5{MUi4PVM1OzxxYU6=
A549	NUn1Sph5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NWP0WpA{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gN{42QCEQvF2u	M17OTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkS3OVU1Lz5zOEK0O\|U2PDxxYU6=
K562	M1;x[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NX3FN4JNPzJiaILz	M1HlcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMz62OkDPxE1w	NUPo[nM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3PFczPjJpPkK5O\|g4OjZ{PD;hQi=>
A375	NWrycoQzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXywc2h3PzJiaILz	NXPNVllWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN\|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFMvPjdizszNMi=>	Mn\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEKzPVcoRjJ7MkCyN\|k4RC:jPh?=
MCF7	Mk\YRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHjUelY1QCCqcoO=	NH3vWndCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuNFIh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN2MESxN{c,Ojh\|NEC0NVM9N2F-
MKN45	NFu0fWFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2NTkS1JINmdGy\|LDDJR\|UxKD1iND6xOkDPxE1w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
MCF7	NWKzS40xTnWwY4Tpc44h[XO\|YYm=			NEXTdWdKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdHNuIFnDOVAhRSB2LkOg{txONg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W1OEc,OTh{NEe1OVQ9N2F-
HL60	Ml\XRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYO0PEBpenN?	M4\5UWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND61N{DPxE1w	NF\YVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO0NFQyOyd-MkizOFA1OTN:L3G+
MDA-MB-231	NXS2THdwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4jZflczKGi{cx?=	NI\WVmpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDh[pRmeiB5MjDodpMh[nliTWTUMYJie2WmIHHzd4F6NCCLQ{WwJF0hPC54MzFOwG0v	M2PBUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe0N\|I3Lz5{NUi3OFMzPjxxYU6=
K562	NInveWZHfW6ldHnvckBie3OjeR?=			M2fGdGlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBx[XK2aXHscJkheHW{aX\p[YQhcGm\|dH;u[UBl\WGlZYT5cIF{\SCxZjDoeY1idiCuZYXr[Y1q[SCNNU[yJINmdGy\|LjygTWM2OCB;IESuPEDPxE1w	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR{NUGxNEc,OTB2MkWxNVA9N2F-
HeLa	NIflNnBHfW6ldHnvckBie3OjeR?=			NUTXXpd6UW6qaXLpeIlwdiCxZjDISGFEKG[{b32gbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bw\iCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uMEBKSzVyIE2gOE45KM7:TT6=	NFrtfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzOFU{PCd-MUm1N\|Q2OzR:L3G+
MGC803	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF;oNHg4OiCqcoO=	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2JQ{iwN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO\|YYmsJGlEPTBiPTC0Mlg6KM7:TT6=	NVvTbWNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyNFI{QTdpPkK5NlAzOzl5PD;hQi=>
PC3	MlS0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M4HVfVQ5KGi{cx?=	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPC56OTFOwG0v	NYjoVmU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NVE6ODZpPkK4OVEyQTB4PD;hQi=>
HuH7	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		NYLPRoF1OyCmYYnz	NInrOHNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJfUh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDD2bYFjcWyrdImgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncjC5OkBie3OjeTygR2M2OCB;IEWuNUDPxE1w	NX3oVGJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVA4ODBpPkK1OFkxPzByPD;hQi=>
HCT116	MnHER5l1d3SxeHnjbZR6KGG\|c3H5		MWq3NkBpenN?	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFUvOSEQvF2u	NYmzdlFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOFA6PjFpPkK2NVQxQTZzPD;hQi=>
A549	NFnXSnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUW3NkBpenN?	M2jXfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQu[mG\|ZXSgZZN{[XluIFnDOVAhRSB3LkSxJO69VS5?	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{SzNlYoRjJ3OEe0N\|I3RC:jPh?=
A549	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWDsfFM1PzJiaILz	NHPrOmlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNT60NUDPxE1w	NFvlNog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm1N\|czOid-MkW5OVM4OjJ:L3G+
A2780	MmrKRY51cWOjbnPldkBie3OjeR?=		NGm2NG44OiCqcoO=	NIjIe3dCdnSrY3HuZ4VzKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0liPTC1Mlch\|ryPLh?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUizOEc,OjF5NEG4N\|Q9N2F-
A549	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkHaOFghcHK\|	M1roZ2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSB3Lke2JO69VS5?	M{L2UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{m1NVUxLz5{OEO5OVE2ODxxYU6=
A2780	MmSzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mn35OFghcHK\|	NH;oWXRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1Mlg6KM7:TT6=	NYe1SHZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOFA1OTNpPkK4N\|QxPDF\|PD;hQi=>
SMMC7721	MkHuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH;PRnQ4OiCqcoO=	M4jZRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU13NR\|c4OjFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hPS57NzFOwG0v	NGrSTY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlM6Pyd-MkmyNFI{QTd:L3G+
U266	NWnmSHdHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1S3Z\|Q5KGi{cx?=	NHn1WHNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWyOlYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IE[uNUDPxE1w	NIrxblY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxOVAxQSd-Mki0NVUxODl:L3G+
PC3	NI\HVXJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NI\abYY1QCCqcoO=	NH34eFRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNj6zOkDPxE1w	M1K3e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{SwOFE{Lz5{OEO0NFQyOzxxYU6=
U251	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoHhNkBl[Xm\|	NXG4N3YzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxteyCjZoTldkAzKGSjeYOgZpkhVVSWIHHzd4F6NCCJSUWwJF0hPi53IN88UU4>	NE\Bc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVM6PCd-MkK1OFE{QTR:L3G+
NCI-H1299	NG\nSpdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3npNVczKGi{cx?=	M4\vbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgyOjl7IHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDZwN{Sg{txONg>?	MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEKzPVcoRjJ7MkCyN\|k4RC:jPh?=
AsPC1	NVruPG1NT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1\H[FQ5KGi{cx?=	MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBd3BEOSClZXzsd{Bi\nSncjC0PEBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDZwOTFOwG0v	Mmq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|OUWxOVAoRjJ6M{m1NVUxRC:jPh?=
BGC823	Mm\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFj5UnM4OiCqcoO=	MVPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDCS2M5OjNiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVKGS7ZTDy[YR2[3Srb36gZZN{[XluIFfJPVAhRSB5LkGg{txONg>?	M1\vTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
MCF7	NV;oOoZiS3m2b4TvfIlkcXS7IHHzd4F6		M2XvNFczKGi{cx?=	NUDVUY1xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPy56OEGg{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF2MEm2NUc,OjZzNEC5OlE9N2F-
DU145	NVTaelVLSW62aXPhcoNmeiCjc4PhfS=>		NXXiNHd6PzJiaILz	NUO2WFZVSW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLIE2gO{46KM7:TT6=	NH\2[WM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NVg{PCd-MkG3OFE5OzR:L3G+
Bel7402	NHT6RlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH7Mb3o4OiCqcoO=	MonOS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRoVtPzRyMjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEig{txONg>?	NFvQfpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NVM4Pid-MkOwOlE{PzZ:L3G+
HeLa	M1S5S2Z2dmO2aX;uJIF{e2G7		MoLjNlAhdWmwcx?=	NFruXGdKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUGWOYTDj[YxteyC3c3nu[{BndHWxcjDk[UBNgXNiYYOgd5Vje3S{YYTlJIlv[3WkYYTl[EBnd3JiMkCgcYlveyCkeTDtbYNzd3CuYYTlJJNx\WO2cn;mcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA5NjB{IN88UU4>	NHjOTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3PCd-MkewOlA4PjR:L3G+
MGC803	NU\oWJB2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoPIO\|IhcHK\|	MoS5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWdEQDB\|IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JHdUXCCmeXWgdoVlfWO2aX;uJIF{e2G7LDDHTVkxKD1iOD65JO69VS5?	M1TRTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
K562	MoX0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MnTIOFghcHK\|	Mmq0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSB7LkOyJO69VS5?	M4DsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkK5OlMxLz5{OE[yPVY{ODxxYU6=
SMMC7721	M{nQ[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1vkUVczKGi{cx?=	NYDQVJBLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW02PQ{e3NlEh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliV2PUJIR6\SC{ZXT1Z5Rqd25iYYPzZZktKEeLOUCgQUAyOSEQvF2u	M4XtdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[xN\|c3Lz5{M{C2NVM4PjxxYU6=
HeLa	NIDkbmVHfW6ldHnvckBie3OjeR?=		M1LxcVI1KHSxIES4JIhzew>?	NVXGWZQxUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKEinTHGgZ4VtdHNidYPpcochSm:lLVz5d{hCSylvQV3DJIF{KHO3YoP0doF1\SCjZoTldkAzPCC2bzC0PEBpenNiYomgd5Bm[3S{b3\seY9zd22ndIL5MEBKSzVyIE2gNVEvOThizszNMi=>	Moj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7OU[zO\|IoRjJ4OUm2N\|czRC:jPh?=
HeLa	MmLxSpVv[3Srb36gZZN{[Xl?			NF\Ge2NKdmirYnn0bY9vKG:oIFjERWMhcW5iSHXMZUBk\WyuczygTWM2OCB;IEGyMlU5QTJizszNMi=>	NI\afFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wOlM4OCd-MUe2NFY{PzB:L3G+
SKHEP1	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUS3NkBpenN?	M2fPXWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMUEWSMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RiZInlJJJm\HWldHnvckBie3OjeTygS2k6OCB;IEGzJO69VS5?	MoGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkGzO\|YoRjJ\|ME[xN\|c3RC:jPh?=
A549	M3n1fWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1G1N\|Q5KGi{cx?=	MoS3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzOD6zO{DPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{OU[zNEc,Ojh4Mkm2N\|A9N2F-
PC3	M2\WOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEPvVXo1QCCqcoO=	M{K3ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzOT6wPUDPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ{OU[zNEc,Ojh4Mkm2N\|A9N2F-
HeLa	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MX:0PEBpenN?	MojORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSBzOT6yOEDPxE1w	NF\vOoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[yPVY{OCd-Mki2Nlk3OzB:L3G+
MCF7	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF7ZUJo1QCCqcoO=	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NEA:KDF7LkK2JO69VS5?	M2S1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkK5OlMxLz5{OE[yPVY{ODxxYU6=
HCT116	Mne3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWDycoZqPDhiaILz	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMkeuOFch\|ryPLh?=	M{f5b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{CxN\|AyLz5zOEewNVMxOTxxYU6=
U251	MnnVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHrZZW4zKGSjeYO=	M2TE[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscJMh[W[2ZYKgNkBl[Xm\|IHL5JG1VXCCjc4PhfUwhXEeLIE2gOFAh\|ryPLh?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUO5OEc,OjJ3NEGzPVQ9N2F-
HEK293 STF	M1vETGZ2dmO2aX;uJIF{e2G7		M{fzVVI1KGi{cx?=	MWDBZ5RqfmG2aX;uJI9nKG2xdYPlJHdvfDOjIIPp[45idGmwZzDlfJBz\XO\|ZXSgbY4hUEWNMkmzJHNVTiClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0doFve2O{aYD0bY9v[WxiYXP0bZZqfHliYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[U1j[XOnZDDsZYN1[XSnIHTlbJllem:pZX7hd4Uh[XO\|YYmu	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTB{Mk[3OUc,OTlyMkK2O\|U9N2F-
U937	NF;TbmlHfW6ldHnvckBie3OjeR?=	M2fYdVUhfU1?	NHfUOGczPCCqcoO=	NXTEbIU4UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvckBqdiCXOUO3JINmdGy\|IHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcz6=	NVzuOpprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0OFc4PTBpPkG3OFQ4PzVyPD;hQi=>
U937	MULGeY5kfGmxbjDhd5NigQ>?			NUnLb4N6UW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNUBqdiCXOUO3JINmdGy\|IHL5JIludXWwb4Dy[YNqeGm2YYTpc44h[XO\|YYmu	NFzXbo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	MmLISpVv[3Srb36gZZN{[Xl?			NYThZoN1UW6mdXP0bY9vKG:oIHjpd5RwdmViSESgbJlx\XKjY3X0fYxifGmxbjDpckBpfW2jbjDVPVM4KGOnbHzzMi=>	NG\QU4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	MXTGeY5kfGmxbjDhd5NigQ>?			MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN2IHnuJHU6OzdiY3XscJMh[nliaX3teY5weHKnY3nwbZRifGmxbjDhd5NigS5?	NH;CbXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEO4NVI{QCd-MUizPFEzOzh:L3G+
U937	MWXGeY5kfGmxbjDhd5NigQ>?			MVLJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdiCrbjDoeY1idiCXOUO3JINmdGy\|Lh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDN6MUKzPEc,OTh\|OEGyN\|g9N2F-
HCT116	M{LUc2Z2dmO2aX;uJIF{e2G7	MlTFNVAhfU1?	NGi4TYwzPCCqcoO=	NWThdJAyUW6qaXLpeIlwdiCxZjDISGFEOSCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCBzMDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{Ng>?	NV3jfpV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVIzOjZpPkKwOFUzOjJ4PD;hQi=>
NB4	M3:4XWNmdGxiY4njcIUh[XK{ZYP0JIF{e2G7	NFm1[nU2KHWP	NI\4SXgzPCCqcoO=	Mlq2R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUmI1KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHjZ5VufWyjdHnvckBifCCycnWtS\|EheGijc3WgZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliRlHDV{BidmGueYPpd{4>	M4TTVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNEmxOFQxLz5{MES5NVQ1ODxxYU6=
NB4	M2H5RWZ2dmO2aX;uJIF{e2G7	MYS1JJVO	MlHNNlQhcHK\|	MoLPTY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;uJIlvKGi3bXHuJG5DPCClZXzsd{BifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMv	NV;obIdFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0PVE1PDBpPkKwOFkyPDRyPD;hQi=>
epithelial cells	NXzoWndwTnWwY4Tpc44h[XO\|YYm=	NXP2PGpiOSC3TR?=	M{fCU\|QtKDZuIHHu[EA5KGSjeYO=	M4raV2lvcGmkaYTpc44hd2ZiSFTBR\|chcW5iaIXtZY4hcG:vb4r5[492eyCIZHXseIE2ODhicILpcYFzgSCkcn;uZ4hq[WxiZYDpeIhmdGmjbDDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|IHH0JFEhfU1iZn;yJFQtKDZuIHHu[EA5KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcE4>	M1rnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[2O\|g6Lz5zOUm2Olc5QTxxYU6=
Hela	NGPjTnZHfW6ldHnvckBie3OjeR?=	M1\0R\|AvPiC3TR?=	MWKxOkBpenN?	MUjJcohq[mm2aX;uJI9nKEiGQVO2JIlvKGi3bXHuJGhmdGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6geI91[WxibInzbY5mKGGlZYT5cIF1cW:wIHH0JFAvPiC3TTDh[pRmeiBzNjDodpMh[nliaX3teY5w\my3b4Lld4NmdmOnIH3pZ5Jwe2OxcImu	NEfKc\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[5Olk2Pid-MkG2PVY6PTZ:L3G+
U937	MWfD[YxtKGO7Y3zlJIFzemW\|dDDhd5NigQ>?	MnjFOUB2VQ>?	Ml3zN\|AhcHK\|	M1vzPGNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEWgeW0h[W[2ZYKgN\|AhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkv	M1:yRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkG1OlQ4Lz5{MUKxOVY1PzxxYU6=
epithelial cells	NYfTfoNkTnWwY4Tpc44h[XO\|YYm=	MWe1JJVO		MWjJcohq[mm2aX;uJI9nKEiGQVOgbY4hcHWvYX6gdJJqdWG{eTDido9v[2irYXyg[ZBqfGinbHnhcEBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gZZBq[2GuIIP1doZi[2VibH;jZYxqgmG2aX;uJIF1KDVidV2u	NHLuOI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
NB4	MUPGeY5kfGmxbjDhd5NigQ>?	MmH1OUB2VQ>?	MljyNlQhcHK\|	MnPDTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJG5DPCClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9vKGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR7MUS0NEc,OjB2OUG0OFA9N2F-
C127-LT	NHrLdVhHfW6ldHnvckBie3OjeR?=	NIi2SW0yKHWP	NF;V[JMzPCCqcoO=	MVHJcohq[mm2aX;uJI9nKEiGQVOgbY4hdW:3c3WgR\|EzPy2OVDDj[YxteyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKEWJRmCg[ZhxemW\|c3nvckBifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDmcJVwemW\|Y3XuZ4UhdWmlcn;zZ49xgS5?	NGG5Too9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm5OlM4Oid-Mk[5PVY{PzJ:L3G+
C127-LT	MlLlSpVv[3Srb36gZZN{[Xl?	MV:xNEB2VQ>?	M3:1UFI1KGi{cx?=	M1z1NWlvcGmkaYTpc44hd2ZiSFTBR{BqdiCvb4Xz[UBEOTJ5LVzUJINmdGy\|IHHzd4V{e2WmIHHzJIFkfGm4YYTpc44hd2ZiRVfGVEBmgHC{ZYPzbY9vKGG2IEGwJJVOKGGodHXyJFI1KGi{czDifUBndHWxcnXzZ4Vv[2VibXnjdo9{[2:yeT6=	NWjRR5FGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5PVY{PzJpPkK2PVk3Ozd{PD;hQi=>
HCT116	NUnFbI9lTnWwY4Tpc44h[XO\|YYm=	M3KzfFExKHWP	MWeyOEBpenN?	MXjJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDofZBmemGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN{MUKxOUc,OjJ\|MkGyNVU9N2F-
HCT116	NEnmcYpHfW6ldHnvckBie3OjeR?=	MUmxNEB2VQ>?	M{jQW\|I1KGi{cx?=	M1PNVmlvcGmkaYTpc44hd2ZiSFTBR\|EhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YhcGm\|dH;u[UBJOyCjdDCxNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|Lh?=	NVTSTndKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzNlEzOTVpPkKyN\|IyOjF3PD;hQi=>
TC32	MULxTHRUKGG\|c3H5			NX7S[HJFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIOu	M4HoPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	M{PrfJFJXFNiYYPzZZk>			NFn3ZXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzzMi=>	NVTlOmE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	NFPyfIdyUFSVIHHzd4F6			M17UOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|Lh?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MX\xTHRUKGG\|c3H5			NYjNblFTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIOu	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MmDWdWhVWyCjc4PhfS=>			M3fmTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIOu	NHXzNJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MVPxTHRUKGG\|c3H5			MlrsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|Lh?=	Mk\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NXvoXXpVeUiWUzDhd5NigQ>?			M4Pie5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtey5?	NXXTSVU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	M3zwZZFJXFNiYYPzZZk>			NXThfJpOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJMv	MmjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	M4C1cpFJXFNiYYPzZZk>			NFG4VlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIOu	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NX3oXndteUiWUzDhd5NigQ>?			NWDyd\|MzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzzMi=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NFH2VmRyUFSVIHHzd4F6			NWrNTJdEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsd{4>	NHTacZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	Mkj3dWhVWyCjc4PhfS=>			NHPhR3FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzzMi=>	NGrYVpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast cells	Mn7rdWhVWyCjc4PhfS=>			MlzpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKGOxboTyc4whUGhid3ns[EB1gXCnIH\pZpJw[myjc4SgZ4VtdHNw	NGX0eIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NEntOpVyUFSVIHHzd4F6			NX3RdpJLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHNw	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	MYLxTHRUKGG\|c3H5			MlHodWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgSGFQYSClZXzsd{4>	NVTNWmFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NIPrNmpyUFSVIHHzd4F6			MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtey5?	MnnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M17vOpFJXFNiYYPzZZk>			M{H2N5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHNw	NYflSJVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NWC1Xod7eUiWUzDhd5NigQ>?			NVjXXnN5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIOu	M{\mWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NGTIR3lyUFSVIHHzd4F6			NF\WTHpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MS5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MX\xTHRUKGG\|c3H5			MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsd{4>	M2ToOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NYS5cGI2eUiWUzDhd5NigQ>?			NICzWFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtey5?	NYDQO4R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	NH74XlVyUFSVIHHzd4F6			M2nxU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJMv	M1PJNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	MX;xTHRUKGG\|c3H5			M4nCZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtey5?	NHfuZ2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	MXLxTHRUKGG\|c3H5			MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJMv	MorTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NWjpWWUxeUiWUzDhd5NigQ>?			M2TLVpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJMv	M3XKUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NH3ldoJyUFSVIHHzd4F6			M{HpZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJFKGOnbHzzMi=>	MoXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	NH\1VlZyUFSVIHHzd4F6			MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucz6=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MWLxTHRUKGG\|c3H5			MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucz6=	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M3zWWJFJXFNiYYPzZZk>			NIfBfYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsd{4>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	MnO5dWhVWyCjc4PhfS=>			MXnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHNw	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NIPoN21yUFSVIHHzd4F6			Mle3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHNw	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	Mny4dWhVWyCjc4PhfS=>			MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJMv	M2PvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NVXOUpl2eUiWUzDhd5NigQ>?			MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{Ng>?	M4H6UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NIX0ZXZyUFSVIHHzd4F6			MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{Ng>?	NYe4WYd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M4LPSpFJXFNiYYPzZZk>			NVrxS\|Y6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtey5?	NE\ie2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NVva[pV1eUiWUzDhd5NigQ>?			NFPCd\|ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{Ng>?	NIHBeoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	M2\LXZFJXFNiYYPzZZk>			NX7aeWRCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|Lh?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
HeLa	NXrNdIpJTnWwY4Tpc44h[XO\|YYm=	M2DUNFEhfU1?	NXnZcllZPiCqcoO=	NFjsN3VKdmirYnn0bY9vKG:oIFjERWMyN0iGQVOyM2hFSUN\|IHnuJIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaX70doFk\WyudXzhdkBi[2W2eXytbIl{fG:wZTDIOEBt\X[nbIOgZZQhOSC3TTDh[pRmeiB4IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	M{f4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{i3NlYzLz5{OUe4O\|I3OjxxYU6=
MV4-11	NEPxbGRCeG:ydH;zbZMh[XO\|YYm=	MmrhOUB2VQ>?	MYKyOEB1dyB2ODDodpM>	MWfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2YND2xNUBk\WyuczDheEA2KHWPIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBCdm6neHnuJHYuWElic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comu	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|OEm1N{c,Ojl5M{i5OVM9N2F-
MV4-11	NEHHT4FHfW6ldHnvckBie3OjeR?=	MmH0NlAxKG6P	Mkf3NlQhcHK\|	MoL5TY5pcWKrdHnvckBw\iClbHHzd{AyKEiGQVOgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCB{MECgcm0h[W[2ZYKgNlQhcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	NYP2U2Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|g6PTNpPkK5O\|M5QTV\|PD;hQi=>
HL60	NGCye\|hCeG:ydH;zbZMh[XO\|YYm=	MXW1JJVO	NE\YU2E1QCCqcoO=	NFTIVoVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjMOlAh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5icILvZ4F{eGG\|ZT2zJIxmfmWuIHH0JFUhfU1iYX\0[ZIhPDhiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcz6=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDRzNUCwPUc,Ojh2MUWwNFk9N2F-
HL60	MkHCRZBweHSxc3nzJIF{e2G7	M2fadlUhfU1?	NHvJbmg1QCCqcoO=	NYfCdVZjUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPs[YF3\WRiY3HzdIF{\S1\|IHzleoVtKGG2IEWgeW0h[W[2ZYKgOFghcHK\|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqey5?	NHnadHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESxOVAxQSd-Mki0NVUxODl:L3G+
HL60	MlHPRZBweHSxc3nzJIF{e2G7	Ml\LOUB2VQ>?	MU[0PEBpenN?	NYr2NVE{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPs[YF3\WRiUFHSVEBt\X[nbDDheEA2KHWPIHHmeIVzKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOu	MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MUWwNFkoRjJ6NEG1NFA6RC:jPh?=
MV4-11	M2\y[WNmdGxiY4njcIUh[XK{ZYP0JIF{e2G7	MYK1JJVO	Ml7yNlQhcHK\|	MVvD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNWlQuOTFiY3XscJMh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KHO3Yj3HNUBxcGG\|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDt[ZRpd2Rw	NYS2fXdRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1PFk1PDFpPkK5OVg6PDRzPD;hQi=>
HEL	MUXD[YxtKGO7Y3zlJIFzemW\|dDDhd5NigQ>?	MnTuOUB2VQ>?	MVGyOEBpenN?	NGXnZZVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJTUxiY3XscJMh[XRiNTD1UUBi\nSncjCyOEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobH;3JIN6fG:vZYTybYMhdWW2aH;kMi=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV6OUS0NUc,Ojl3OEm0OFE9N2F-
Jurkat	NH7ySJdE\WyuIHP5Z4xmKGG{cnXzeEBie3OjeR?=	MY[1JJVO	M2PtPVI1KGi{cx?=	MlfNR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTpVzc2G2IHPlcIx{KGG2IEWgeW0h[W[2ZYKgNlQhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[E4>	NF3U[Gw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW4PVQ1OSd-Mkm1PFk1PDF:L3G+
MV4-11	MVTGeY5kfGmxbjDhd5NigQ>?	NIKweVM2KHWP	NYDmbJVGOjRiaILz	MnjrTY5pcWKrdHnvckBw\iClbHHzd{AyKEiGQVOgbY4hcHWvYX6gUXY1NTFzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZD6=	M2nwSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUi5OFQyLz5{OUW4PVQ1OTxxYU6=
LNCAP	M2HKTGZ2dmO2aX;uJIF{e2G7	NUjEdZVpOTBidV2=	M4LWV\|I1KGi{cx?=	NFjwc5dKdmirYnn0bY9vKG:oIFjERWM3KGmwIHj1cYFvKEyQQ1HQJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRFjUMYlv\HWlZXSgZYxxcGFvdIXieYxqdiCmZXHj[ZR6dGG2aX;uJIJ6KG2nYYP1dolv\yCrbnPy[YF{\SCrbjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:wIHH0JFExKHWPIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{Bz\WyjdHn2[UB1dyClb370do9tNg>?	NEf0W\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{exO\|U1PCd-Mke3NVc2PDR:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; PubMed: 24203492 Pharm Res HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. Cleaved PARP; PubMed: 19148581 J Neurooncol Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control. Caspase 8 ; PubMed: 19148581 J Neurooncol Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression. DR4 / DR5; PubMed: 19148581 J Neurooncol Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h. TopoIIα / TopoIIβ; PubMed: 21254166 Hepatology Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.	24203492 19148581 21254166
Immunofluorescence	phalloidin / snail; PubMed: 29855565 Sci Rep (C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed. DR4 / DR5; PubMed: 19148581 J Neurooncol Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls. H3K4Me3 / H3K9Me3; PubMed: 22468166 Mol Cell Pharmacol Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.	29855565 19148581 22468166
Growth inhibition assay	Cell proliferation; PubMed: 24203492 Pharm Res (A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. , P < 0.05, ; P ≤ 0.01; **, P ≤ 0.001 Cell viability; PubMed: 28969017 Oncotarget PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.	24203492 28969017
ELISA	GCP-2 / MCP-2 / MIF ; PubMed: 24241152 Molecules MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).	24241152

In vivo

MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. ^[1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. ^[4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. ^[5]

Protocol

Kinase Assay: ^[6]	- Collapse Standard HDAC Assays: Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λ_ex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. K_m and V_max values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research: ^[2]	- Collapse Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells Concentrations: ~ 10 μM Incubation Time: 3 days Method: Cancer cells (5 × 10³) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO₂-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na₂HPO₄ is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice. Dosages: 12.3, 24.5 and 49 mg/kg Administration: Administered orally once daily 5 days per week for 4 weeks (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	75 mg/mL (199.25 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Entinostat (MS-275) SDF

Molecular Weight	376.41
Formula	C₂₁H₂₀N₄O₃
CAS No.	209783-80-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SNDX-275
Smiles	C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04708470	Recruiting	Drug: Bintrafusp Alfa\|Drug: NHS-IL12\|Drug: Entinostat	Cancer\|Solid Tumor\|Metastatic Checkpoint Refractory HPV Associated Malignancies\|Microsatellite Stable Colon Cancer (MSS)	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	September 7 2021	Phase 1\|Phase 2
NCT03829930	Terminated	Drug: Entinostat\|Drug: Enzalutamide	Prostate Adenocarcinoma	George Washington University	May 1 2019	Phase 1
NCT03765229	Recruiting	Drug: Entinostat\|Drug: Pembrolizumab	Melanoma	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals Inc.	March 22 2019	Phase 2
NCT03473639	Recruiting	Drug: Entinostat\|Drug: Capecitabine	Metastatic Breast Cancer\|Breast Cancer	University of Virginia\|Syndax Pharmaceuticals	January 29 2019	Phase 1
NCT03361800	Terminated	Drug: Entinostat	Breast Cancer\|Invasive Breast Cancer\|ER-Negative PR-Negative HER2-Negative Breast Cancer	UNC Lineberger Comprehensive Cancer Center\|Syndax Pharmaceuticals\|National Cancer Institute (NCI)	November 28 2018	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to use Entinostat（Catalog No.S1053） for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?
Answer:
2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Entinostat (MS-275)